GlobeNewswire·Oct 8, 2026, 9:29 PM ET

TRexBio Announces Pricing of Initial Public Offering

TRex Bio, Inc. priced its initial public offering of 8,333,334 common stock shares at $14.00 per share.
The offering is expected to generate approximately $116.7 million in gross proceeds before deducting underwriting discounts & commissions & other expenses.
All shares are being offered directly by TRex Bio.
Shares are scheduled to begin trading on the Nasdaq Global Select Market on October 9, 2026, under the ticker symbol "TRXB".
The offering is expected to close on October 13, 2026, subject to customary closing conditions.
Underwriters have been granted a 30-day option to purchase up to an additional 1,250,000 shares at the initial public offering price.
J.P. Morgan, Evercore ISI, Cantor, & Stifel are acting as lead book-running managers, while Wedbush PacGrow is acting as a book-running manager.
The registration statement (File No. 333-299018) became effective with the SEC on October 8, 2026.
TRex Bio is a clinical-stage biotechnology company focused on tissue Treg biology & immunoregulatory medicines for autoimmune & inflammatory diseases.
The company is headquartered in South San Francisco, California, & utilizes its Deep Biology Platform for drug discovery.